Pfizer Return on Investment 2010-2023 | PFE
Current and historical return on investment (ROI) values for Pfizer (PFE) over the last 10 years.
| Pfizer ROI - Return on Investment Historical Data |
| Date |
TTM Net Income |
LT Investments & Debt |
Return on Investment |
| 2023-12-31 |
$0.22B |
$150.83B |
0.15% |
| 2023-09-30 |
$9.21B |
$158.25B |
6.35% |
| 2023-06-30 |
$21.59B |
$160.65B |
15.76% |
| 2023-03-31 |
$31.88B |
$132.94B |
25.05% |
| 2022-12-31 |
$34.94B |
$128.80B |
28.27% |
| 2022-09-30 |
$33.55B |
$125.52B |
28.00% |
| 2022-06-30 |
$30.76B |
$121.76B |
26.40% |
| 2022-03-31 |
$24.15B |
$118.34B |
21.47% |
| 2021-12-31 |
$19.43B |
$113.66B |
17.84% |
| 2021-09-30 |
$17.15B |
$112.22B |
16.22% |
| 2021-06-30 |
$13.45B |
$105.67B |
12.63% |
| 2021-03-31 |
$9.91B |
$104.21B |
9.11% |
| 2020-12-31 |
$8.25B |
$100.61B |
7.63% |
| 2020-09-30 |
$2.62B |
$115.28B |
2.43% |
| 2020-06-30 |
$3.13B |
$115.09B |
3.00% |
| 2020-03-31 |
$5.32B |
$101.62B |
5.34% |
| 2019-12-31 |
$6.71B |
$99.40B |
6.85% |
| 2019-09-30 |
$5.62B |
$101.44B |
5.78% |
| 2019-06-30 |
$6.43B |
$96.09B |
6.54% |
| 2019-03-31 |
$6.14B |
$94.89B |
6.20% |
| 2018-12-31 |
$5.67B |
$96.67B |
5.62% |
| 2018-09-30 |
$14.00B |
$105.32B |
13.59% |
| 2018-06-30 |
$13.90B |
$99.06B |
13.82% |
| 2018-03-31 |
$13.66B |
$102.37B |
13.80% |
| 2017-12-31 |
$13.72B |
$105.19B |
14.12% |
| 2017-09-30 |
$13.17B |
$95.61B |
14.06% |
| 2017-06-30 |
$12.53B |
$92.89B |
13.43% |
| 2017-03-31 |
$12.26B |
$95.08B |
13.12% |
| 2016-12-31 |
$12.15B |
$91.24B |
13.13% |
| 2016-09-30 |
$12.22B |
$94.04B |
13.13% |
| 2016-06-30 |
$12.56B |
$93.52B |
13.41% |
| 2016-03-31 |
$12.68B |
$91.17B |
13.52% |
| 2015-12-31 |
$11.82B |
$93.74B |
12.42% |
| 2015-09-30 |
$12.14B |
$96.20B |
12.44% |
| 2015-06-30 |
$12.46B |
$93.91B |
12.34% |
| 2015-03-31 |
$12.82B |
$96.96B |
12.23% |
| 2014-12-31 |
$13.25B |
$103.16B |
12.38% |
| 2014-09-30 |
$14.15B |
$109.97B |
13.10% |
| 2014-06-30 |
$14.45B |
$109.22B |
13.37% |
| 2014-03-31 |
$14.78B |
$105.72B |
13.64% |
| 2013-12-31 |
$15.18B |
$107.08B |
13.74% |
| 2013-09-30 |
$14.70B |
$110.17B |
13.13% |
| 2013-06-30 |
$14.46B |
$110.51B |
12.83% |
| 2013-03-31 |
$15.04B |
$114.31B |
13.34% |
| 2012-12-31 |
$15.26B |
$112.71B |
13.45% |
| 2012-09-30 |
$14.62B |
$113.20B |
12.74% |
| 2012-06-30 |
$14.96B |
$110.83B |
12.69% |
| 2012-03-31 |
$14.12B |
$117.22B |
11.63% |
| 2011-12-31 |
$13.97B |
$117.55B |
11.31% |
| 2011-09-30 |
$13.94B |
$125.93B |
11.08% |
| 2011-06-30 |
$13.62B |
$124.69B |
10.80% |
| 2011-03-31 |
$13.80B |
$125.84B |
10.94% |
| 2010-12-31 |
$13.41B |
$126.68B |
10.59% |
| 2010-09-30 |
$11.49B |
$127.08B |
8.94% |
| 2010-06-30 |
$11.85B |
$124.64B |
9.77% |
| 2010-03-31 |
$10.77B |
$128.36B |
9.46% |
| 2009-12-31 |
$10.96B |
$133.64B |
10.72% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$148.755B |
$58.496B |
|
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
|
